ArticleThe Journal of pediatrics2012
Rate of weight gain and cardiometabolic abnormalities in children and adolescents.
Article in The Journal of pediatrics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Bone Mass in Boys with Autism Spectrum Disorder.Journal of autism and developmental disorders · 2017Pooled it
- Serum Ferritin, Weight Gain, Disruptive Behavior, and Extrapyramidal Symptoms in Risperidone-Treated Youth.Journal of child and adolescent psychopharmacology · 2016Trial
- The bidirectional relationship between body mass index and treatment outcome in adolescents with treatment-resistant depression.Journal of child and adolescent psychopharmacology · 2013Trial
- European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment.European child & adolescent psychiatry · 2022Review
- Long-term use of antidepressants, mood stabilizers, and antipsychotics in pediatric patients with a focus on appropriate deprescribing.The mental health clinician · 2021Article
- The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children.Frontiers in psychiatry · 2021Review
- Selective Serotonin Reuptake Inhibitors Reduce Longitudinal Growth in Risperidone-Treated Boys.The Journal of pediatrics · 2018Observational
- Maternal blood cadmium, lead and arsenic levels, nutrient combinations, and offspring birthweight.BMC public health · 2017Article
- Rapid adipose deposition with mood disorders.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists · 2015Article
- Risperidone-induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure.EBioMedicine · 2015Article
- Use of the second-generation antipsychotic, risperidone, and secondary weight gain are associated with an altered gut microbiota in children.Translational psychiatry · 2015Article
- Longitudinal examination of the skeletal effects of selective serotonin reuptake inhibitors and risperidone in boys.The Journal of clinical psychiatry · 2015Article
- Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges.European child & adolescent psychiatry · 2014Article
- Cardiometabolic outcomes in children and adolescents following discontinuation of long-term risperidone treatment.Journal of child and adolescent psychopharmacology · 2014Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo investigate whether the rate of weight gain is associated with cardiometabolic risk, independent of weight measured concurrently. STUDY
designHealthy 7- to 17-year-old risperidone-treated patients (N = 105, 88% were boys) had blood pressure, anthropometry, and laboratory tests performed. Growth history was extracted from medical records. The rate of change in age- and sex-adjusted weight and body mass index (BMI) z score after the initiation of risperidone was individually modeled. Multivariable linear regression analyses explored the association of the rate of weight or BMI z score change with cardiometabolic outcomes, independent of last measured weight or BMI z score, respectively.
resultsFollowing a mean of 1.9 years (SD = 1.0) of risperidone treatment, the absolute increase in weight and BMI z scores was 0.61 (SD = 0.61) and 0.62 (SD = 0.73), respectively. After controlling for the final weight z score, the rate of change in weight z score was significantly associated with final glucose (P < .04), C-peptide (P < .004), the homeostasis model assessment insulin resistance index (P < .02), high-density lipoprotein (HDL) cholesterol (P < .0001), a metabolic syndrome score (P < .005), adiponectin (P < .04), and high-sensitivity C-reactive protein (P < .04). After controlling for the final BMI z score, the rate of change in BMI z score was associated with final HDL cholesterol (P < .04), leptin (P < .03), and adiponectin (P < .04), with a suggestion of an association with the final homeostasis model assessment insulin resistance index (P < .08).
conclusionsCompared with weight measured concurrently, the rate of weight gain in risperidone-treated children accounts for an equal or larger share of the variance in certain cardiometabolic outcomes (eg, HDL cholesterol [ΔR(2) = 8% vs ΔR(2) = 11%] and high-sensitivity C-reactive protein [ΔR(2) = 5% vs ΔR(2) = 9%]) and may serve as a treatment target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.